These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24593263)

  • 1. Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase.
    Haglund J; Halldin MM; Brunnström A; Eklund G; Kautiainen A; Sandholm A; Iverson SL
    Chem Res Toxicol; 2014 Apr; 27(4):601-10. PubMed ID: 24593263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance.
    Yu H; Bischoff D; Tweedie D
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1539-49. PubMed ID: 21067462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
    Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
    Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
    Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
    Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed Matrix Method Provides A Reliable Metabolite Exposure Comparison for Assessment of Metabolites in Safety Testing (MIST).
    Takahashi RH; Khojasteh C; Wright M; Hop CECA; Ma S
    Drug Metab Lett; 2017 Nov; 11(1):21-28. PubMed ID: 28699487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The early estimation of circulating drug metabolites in humans.
    Luffer-Atlas D
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.
    Valentin JP; Bass AS; Atrakchi A; Olejniczak K; Kannosuke F
    J Pharmacol Toxicol Methods; 2005; 52(1):22-9. PubMed ID: 15961324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on non-clinical safety evaluation of drug metabolites through the JSOT workshop.
    Minagawa T; Nakano K; Furuta S; Iwasa T; Takekawa K; Minato K; Koga T; Sato T; Kawashima K; Kurahashi Y; Onodera H; Naito S; Nakamura K
    J Toxicol Sci; 2012; 37(4):667-73. PubMed ID: 22863847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique/major human metabolites: why, how, and when to test for safety in animals.
    Luffer-Atlas D
    Drug Metab Rev; 2008; 40(3):447-63. PubMed ID: 18642142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
    Smith DA; Obach RS
    Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Much Nonclinical Safety Data Are Required for a Clinical Study in Ophthalmology?
    Novack GD; Moyer ED
    J Ocul Pharmacol Ther; 2016; 32(1):5-10. PubMed ID: 26539734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
    Timmerman P; Anders Kall M; Gordon B; Laakso S; Freisleben A; Hucker R
    Bioanalysis; 2010 Jul; 2(7):1185-94. PubMed ID: 21083233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA; Obach RS
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
    Piana C; Kliphuis E; Della Pasqua O
    Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?
    Gao H; Jacobs A; White RE; Booth BP; Obach RS
    AAPS J; 2013 Oct; 15(4):970-3. PubMed ID: 23821354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.